P1/2, N=54, Not yet recruiting, M.D. Anderson Cancer Center

P1, N=34, Completed, MiNK Therapeutics | Recruiting --> Completed

P1/2, N=23, Recruiting, Radboud University Medical Center | Trial completion date: Sep 2023 --> Sep 2025 | Trial primary completion date: Sep 2023 --> Sep 2025

The unique architecture of this biomaterial complex protects NK cells from the hostile tumor environment and improves antitumor efficacy. The generation of a transient inflammatory niche for NK cells through a biocompatible hydrogel reservoir may be a conversion pathway to prevent cancer recurrence of resectable tumors.

P1, N=15, Suspended, M.D. Anderson Cancer Center | Recruiting --> Suspended

P=N/A, N=100, Recruiting, Nanjing University School of Medicine

P2, N=53, Completed, Celgene | Trial primary completion date: Nov 2018 --> Sep 2023

P1, N=0, Withdrawn, Escure Biotechnology Corp | N=20 --> 0 | Recruiting --> Withdrawn

P1, N=42, Not yet recruiting, M.D. Anderson Cancer Center

MTT and flow cytometry were used to assess cell viability and apoptosis in EC18 and TE1 cells, while wound healing and transwell assays were used to investigate cell migration and invasion in vitro...I3C promoted ESCC apoptosis and inhibited cell migration and invasion by downregulating β-catenin, c-myc, and cyclin D1 in vitro and decreased the tumor growth in vivo; this process was reversed by LiCl treatment. In summary, I3C inhibits ESCC malignant behavior by suppressing the Wnt/β-catenin signaling pathway, thus deeming it a promising drug for ESCC treatment.

P1, N=7, Terminated, Sanofi | Trial completion date: Jan 2025 --> Mar 2024 | Active, not recruiting --> Terminated; Sponsor's decision

P1, N=44, Suspended, M.D. Anderson Cancer Center | Not yet recruiting --> Suspended

P1, N=56, Recruiting, Kyushu University | N=36 --> 56

P1, N=160, Recruiting, D2M Biotherapeutics Inc. | Active, not recruiting --> Recruiting

P1, N=160, Active, not recruiting, D2M Biotherapeutics Inc.

P1/2, N=20, Completed, MiNK Therapeutics | Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Apr 2023 | Trial primary completion date: Aug 2023 --> Apr 2023

P1/2, N=82, Recruiting, 23andMe, Inc. | Not yet recruiting --> Recruiting

P1, N=21, Not yet recruiting, Senti Biosciences

P1, N=18, Not yet recruiting, Dana-Farber Cancer Institute

P1, N=5, Not yet recruiting, Dana-Farber Cancer Institute

More importantly, CAR-NK cells combined with immune checkpoint inhibitors, anti-PD-L1, could synergistically enhance the antitumor efficacy of CLDN6-targeted CAR-NK cells. These results indicate that CLDN6-CAR NK cells possess strong antitumor activity and represent a promising immunotherapeutic modality for ovarian cancer.

P1, N=12, Completed, Deverra Therapeutics, Inc. | Recruiting --> Completed | N=18 --> 12

P1, N=18, Recruiting, Deverra Therapeutics, Inc. | Trial completion date: Jun 2023 --> Jul 2024 | Trial primary completion date: Dec 2022 --> Jun 2024

Multi-agent regimens incorporating immunomodulatory (IMiD®) agents such as thalidomide, lenalidomide, and pomalidomide have become the preferred standard of care for the treatment of patients with multiple myeloma (MM), resulting in improved survival outcomes. Here, we discuss AEs associated with pomalidomide and present five clinically relevant hypothetical case studies in patients with RRMM to provide scenario-driven guidance regarding treatment selection and AE prevention and management in the clinical setting. Lastly, as new treatment approaches continue to be explored in MM, we also discuss novel cereblon E3 ligase modulator (CELMoD™) agents including iberdomide (CC-220) and mezigdomide (CC-92480).

Finally, in patient marrow specimens, CC-96191 eliminated AML cells but not normal monocytes, suggesting selectivity of TriNKET-induced cytotoxicity toward neoplastic cells. Together, these findings support the clinical exploration of CC-96191 as in NCT04789655.

P1/2, N=184, Recruiting, Innate Pharma | Not yet recruiting --> Recruiting | Initiation date: Oct 2023 --> Mar 2024

P2, N=29, Active, not recruiting, Emory University | Trial completion date: Aug 2024 --> Mar 2026 | Trial primary completion date: Jul 2024 --> Mar 2025

P1, N=322, Recruiting, Fate Therapeutics | Trial completion date: Dec 2039 --> Jun 2044 | Trial primary completion date: Dec 2024 --> Jun 2029

P2, N=0, Withdrawn, Sanofi | N=107 --> 0 | Trial completion date: Feb 2027 --> Oct 2027 | Not yet recruiting --> Withdrawn

Based on the cocultures, adding pomalidomide significantly promoted IFN-γ and TNF-α secretion (P < .05). Based on the above clinical and in vitro studies demonstrating the co-administration of pomalidomide with CAR-T cell treatment demonstrated favorable tolerability and therapeutic effectiveness in RRMM or B-cell leukemia/lymphoma.

P1/2, N=82, Not yet recruiting, 23andMe, Inc.

P1/2, N=362, Recruiting, Dragonfly Therapeutics | Trial primary completion date: Oct 2023 --> Oct 2024

P1/2, N=24, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Dec 2027 --> Jun 2024 | Trial primary completion date: Dec 2027 --> Jun 2024

P1, N=6, Active, not recruiting, NKGen Biotech, Inc. | Recruiting --> Active, not recruiting | N=12 --> 6

P1/2, N=11, Terminated, NKGen Biotech, Inc. | N=121 --> 11 | Trial completion date: Nov 2025 --> Sep 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2025 --> Sep 2023; Affimed and NKGen have mutually decided to discontinue the study. Affimed will evaluate the best options to advance this project with an allogeneic off-the-shelf NK cell product while NKGen will focus on CNS with SNK01.

P1, N=10, Terminated, NKGen Biotech, Inc. | N=30 --> 10 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Aug 2023; The study was terminated after completing the dose escalation portion of the study. The expansion cohort was not initiated to conduct a global trial based on the approved US IND using a new manufacturing process.

P1, N=15, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting | Initiation date: May 2024 --> Jan 2024

P1, N=10, Active, not recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Active, not recruiting

P1, N=55, Recruiting, Shanghai Simnova Biotechnology Co.,Ltd. | Initiation date: Jan 2024 --> Apr 2024

P1, N=7, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting | N=12 --> 7

P1/2, N=56, Active, not recruiting, Cristina Gasparetto | Trial completion date: Jan 2023 --> Jan 2025

P2, N=17, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=190 --> 17